|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right-of-use assets - operating leases | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Short-term operating lease liabilities | ||||||||||||||||||||
| Short-term finance lease liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term operating lease liabilities | ||||||||||||||||||||
| Long-term finance lease liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Contingently redeemable warrants | ||||||||||||||||||||
| Stockholders’ equity (deficiency): | ||||||||||||||||||||
| Preferred stock value | ||||||||||||||||||||
| Series A Convertible Preferred Stocks | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Series D Convertible Preferred Stock | ||||||||||||||||||||
| Common stock of $0.01 par value – authorized 300,000,000 shares: issued and outstanding 1,779,275 shares as of June 30, 2026 and 929,597 shares as of June 30, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity (deficiency) | ||||||||||||||||||||
| Total liabilities and stockholders’ equity (deficiency) | ||||||||||||||||||||
Loading...
